Skip to main content
. 2022 Jul 25;61(10):1457–1469. doi: 10.1007/s40262-022-01147-w

Fig. 3.

Fig. 3

Time to pulmonary exacerbation by post-baseline sputum neutrophil elastase concentration. All patients (a) and brensocatib-treated patients (b) with neutrophil elastase BLQ post-baseline experienced significantly fewer exacerbations than those with detectable neutrophil elastase. BLQ below the level of quantification